ALTA-3263 / Alterome Therap - LARVOL DELTA

Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors (Businesswire) - "Alterome Therapeutics...announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors....The Phase 1/1b, open-label, dose-escalation and multiple cohort study is evaluating the safety, tolerability, pharmacokinetics, and preliminary clinical activity of ALTA3263 in adults with advanced unresectable or metastatic solid tumors with KRAS mutations (NCT06835569)."

Trial status • Solid Tumor

A Study to Learn About Study Medicine ALTA3263 in Adults with Advanced Solid Tumors with KRAS Mutations (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: Alterome Therapeutics, Inc.

New P1 trial • Colorectal Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium (Businesswire) - "IND-enabling studies are ongoing to support clinical trial initiation in early 2025....Alterome Therapeutics....today announced that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain....ALTA3263 induced complete and sustained tumor regressions in 8 KRAS G12V/D/C/A mutant xenograft models, including complete responses in 2 patient-derived xenograft non-small cell lung cancer models, while being well-tolerated during prolonged daily oral dosing in mice."

New trial • Preclinical • Non Small Cell Lung Cancer • Oncology

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives (Businesswire) - "Alterome Therapeutics, Inc...announced the closing of a $132 million Series B financing. Proceeds from the fundraise will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor."

Financing • Oncology